Align Technology to Report Q2 2026 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 30 2025
0mins
Align Technology's stock rose by 6.47% as it crossed above the 5-day SMA, reflecting positive investor sentiment ahead of its upcoming earnings report.
The company is set to report its Q2 2026 financial results on July 29, which is expected to provide insights into its performance and growth in the digital orthodontics market. Align's commitment to transparency and investor communication is evident as it plans to host a conference call following the earnings release. This proactive approach, combined with the significant market opportunity of 600 million consumers for its products, positions Align favorably despite the recent EU antitrust investigation.
The upcoming earnings report could serve as a pivotal moment for Align Technology, potentially influencing its stock performance and investor confidence in the face of regulatory challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALGN
Wall Street analysts forecast ALGN stock price to rise
13 Analyst Rating
8 Buy
4 Hold
1 Sell
Moderate Buy
Current: 188.390
Low
169.00
Averages
198.70
High
220.00
Current: 188.390
Low
169.00
Averages
198.70
High
220.00
About ALGN
Align Technology, Inc. is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad computer-aided design and computer-aided manufacturing (CAD/CAM) software for digital orthodontics and restorative dentistry. The Company provides Align Digital Platform. Its segments include Clear Aligner, and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment consists of comprehensive products, non-comprehensive products and non-case products. Its comprehensive products include Invisalign Comprehensive and Invisalign First. The Company's non-case products include retention products, Invisalign training and adjusting tools. It offers up to four sets of custom clear aligners called Vivera retainers. The Systems and Services segment consists of its iTero intraoral scanning systems. Its services include subscription software, disposables, rentals, leases and pay per scan services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Illumina Positioned for Strong Growth Ahead
- Focus on Core Genomics: Following the spin-off of GRAIL in June 2024, Illumina has sharpened its strategy on the core sequencing business, aiming for high-single-digit revenue growth and double-digit to teens EPS growth by 2027, demonstrating a commitment to sustainable growth.
- NovaSeq X Deployments: In Q1 2026, Illumina placed over 80 NovaSeq X units, exceeding expectations and reflecting strong clinical demand, with plans to maintain an average deployment of 50 to 60 units quarterly, further solidifying its market position.
- Clinical Demand Driving Growth: Clinical sequencing consumables demand grew 20% year-over-year in Q1 2026, indicating broader adoption of NGS testing, with expectations that most clinical volumes will transition to the NovaSeq X platform by the end of 2026.
- Challenges in China Market: Despite strong overall performance, Illumina's revenues in Greater China fell 27.8% year-over-year, facing regulatory and geopolitical uncertainties that limit growth potential in the region and may impact overall performance.
See More
Align Technology to Report Q2 2026 Financial Results on July 29
- Earnings Release Schedule: Align Technology will report its Q2 2026 financial results on July 29 after market close, with results available at 4:00 PM ET (1:00 PM PT), reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: Following the earnings release, Align will host a conference call at 4:30 PM ET (1:30 PM PT), with pre-registration available on the company website, indicating a desire for close engagement with investors and real-time feedback.
- Digital Transformation Progress: The Invisalign system has treated approximately 22.8 million patients, showcasing Align's leadership in digital dentistry while providing efficient digital workflows for around 299,500 doctor customers, further solidifying its market share.
- Market Opportunity: Align's products and services tap into a global consumer market opportunity of 600 million, highlighting the company's extensive influence and growth potential in the digital orthodontics and restorative dentistry sectors.
See More
Align Technology Responds to EU Antitrust Investigation
- Antitrust Investigation Launched: The European Commission initiated a formal antitrust investigation against Align Technology on June 30, 2026, based on a competitor's complaint, aiming to determine potential violations of EU competition laws that could impact the company's market position.
- Focus of Investigation: The inquiry centers on two measures taken by Align since 2017, including the refusal to approve competing state-of-the-art scanners for digital scan submissions and the rejection of scans from other intra-oral scanners, despite compliance with industry-standard files, which may limit market competition.
- Company's Response: Align Technology believes the investigation is purely procedural and reiterated the performance capabilities of its proprietary iTero intra-oral scanner; while not directly addressing the allegations of intentional exclusivity, it emphasized that the iTero platform can be used for aligners other than Invisalign.
- Market Performance Overview: Align's stock has traded between $122.00 and $208.31 over the past year, closing at $168.66 on Tuesday with a decline of 2.75%, and in pre-market trading, shares are down slightly to $168.52, reflecting market concerns regarding the investigation.
See More
Align Technology Pushes Back Against EU Investigation
- Market Success Defense: Align Technology (ALGN) asserts that its success in the teeth-straightening market is driven by innovation rather than unfair practices, emphasizing that the quality, innovation, and customer experience of its products and services form the foundation of its market advantage.
- Antitrust Investigation Initiated: The European Commission has launched an antitrust investigation into Align Technology, alleging that the company tied its Invisalign products to its iTero intra-oral scanners, potentially stifling competition, which Align strongly disputes.
- Procedural Step Clarification: Align Technology clarifies that the Commission's investigation is a procedural step aimed at gathering information and does not imply a conclusion on the merits of the case or an accusation of wrongdoing, stressing its commitment to fully cooperate with the inquiry.
- Executive Changes Context: Amid the EU antitrust probe, Align Technology is also undergoing a board shakeup, with Kevin Conroy set to succeed retiring Chairman C. Raymond Larkin, which may influence the company's strategic direction moving forward.
See More
Align Technology Responds to EU Investigation
- Investigation Response: Align Technology has responded to the European Commission's June 30 announcement regarding an investigation, asserting its commitment to global competition laws and the belief that fair competition fosters innovation and improves outcomes for doctors and patients.
- iTero Platform Strength: The iTero intraoral scanning platform performs millions of scans annually, supporting diverse clinical workflows while ensuring clinical quality and patient safety, showcasing its competitive edge in the digital dentistry market.
- Market Impact: Since 2018, the iTero scanner has facilitated over 24 million scans by healthcare professionals, highlighting its extensive application and influence in the teeth-straightening market, driving diversification in digital dentistry solutions.
- Commitment to Cooperation: Align Technology expresses its intention to fully cooperate with the European Commission's investigation, anticipating that the review will reflect the vibrancy and compliance of the teeth-straightening market, further solidifying its market position.
See More
European Commission Launches Antitrust Investigation into Align Technology
- Antitrust Investigation Launched: The European Commission has initiated an antitrust investigation into Align Technology, alleging that the company tied its Invisalign products to its iTero intra-oral scanners, potentially stifling competition and harming its reputation.
- Concerns Over Market Dominance: The Commission is worried that Align Technology may have unfairly leveraged its market-leading Invisalign clear aligners by effectively forcing dental professionals to purchase the iTero scanner to order Invisalign for their patients, which could lead to market inequities.
- Restrictive Interoperability Strategy: The investigation focuses on Align's so-called 'restrictive interoperability strategy,' which includes refusal to approve competing state-of-the-art scanners and refusal to accept dental professionals' submissions of scans, potentially hindering industry innovation.
- Uncertain Financial Outlook: Although Align Technology forecasts Q2 revenue between $1.04 billion and $1.06 billion and reaffirms a 3%-4% revenue growth for 2026, the antitrust investigation may negatively impact its future performance.
See More
Illumina Positioned for Strong Growth Ahead
- Focus on Core Genomics: Following the spin-off of GRAIL in June 2024, Illumina has sharpened its strategy on the core sequencing business, aiming for high-single-digit revenue growth and double-digit to teens EPS growth by 2027, demonstrating a commitment to sustainable growth.
- NovaSeq X Deployments: In Q1 2026, Illumina placed over 80 NovaSeq X units, exceeding expectations and reflecting strong clinical demand, with plans to maintain an average deployment of 50 to 60 units quarterly, further solidifying its market position.
- Clinical Demand Driving Growth: Clinical sequencing consumables demand grew 20% year-over-year in Q1 2026, indicating broader adoption of NGS testing, with expectations that most clinical volumes will transition to the NovaSeq X platform by the end of 2026.
- Challenges in China Market: Despite strong overall performance, Illumina's revenues in Greater China fell 27.8% year-over-year, facing regulatory and geopolitical uncertainties that limit growth potential in the region and may impact overall performance.
See More
Align Technology to Report Q2 2026 Financial Results on July 29
- Earnings Release Schedule: Align Technology will report its Q2 2026 financial results on July 29 after market close, with results available at 4:00 PM ET (1:00 PM PT), reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: Following the earnings release, Align will host a conference call at 4:30 PM ET (1:30 PM PT), with pre-registration available on the company website, indicating a desire for close engagement with investors and real-time feedback.
- Digital Transformation Progress: The Invisalign system has treated approximately 22.8 million patients, showcasing Align's leadership in digital dentistry while providing efficient digital workflows for around 299,500 doctor customers, further solidifying its market share.
- Market Opportunity: Align's products and services tap into a global consumer market opportunity of 600 million, highlighting the company's extensive influence and growth potential in the digital orthodontics and restorative dentistry sectors.
See More
Align Technology Responds to EU Antitrust Investigation
- Antitrust Investigation Launched: The European Commission initiated a formal antitrust investigation against Align Technology on June 30, 2026, based on a competitor's complaint, aiming to determine potential violations of EU competition laws that could impact the company's market position.
- Focus of Investigation: The inquiry centers on two measures taken by Align since 2017, including the refusal to approve competing state-of-the-art scanners for digital scan submissions and the rejection of scans from other intra-oral scanners, despite compliance with industry-standard files, which may limit market competition.
- Company's Response: Align Technology believes the investigation is purely procedural and reiterated the performance capabilities of its proprietary iTero intra-oral scanner; while not directly addressing the allegations of intentional exclusivity, it emphasized that the iTero platform can be used for aligners other than Invisalign.
- Market Performance Overview: Align's stock has traded between $122.00 and $208.31 over the past year, closing at $168.66 on Tuesday with a decline of 2.75%, and in pre-market trading, shares are down slightly to $168.52, reflecting market concerns regarding the investigation.
See More
Align Technology Pushes Back Against EU Investigation
- Market Success Defense: Align Technology (ALGN) asserts that its success in the teeth-straightening market is driven by innovation rather than unfair practices, emphasizing that the quality, innovation, and customer experience of its products and services form the foundation of its market advantage.
- Antitrust Investigation Initiated: The European Commission has launched an antitrust investigation into Align Technology, alleging that the company tied its Invisalign products to its iTero intra-oral scanners, potentially stifling competition, which Align strongly disputes.
- Procedural Step Clarification: Align Technology clarifies that the Commission's investigation is a procedural step aimed at gathering information and does not imply a conclusion on the merits of the case or an accusation of wrongdoing, stressing its commitment to fully cooperate with the inquiry.
- Executive Changes Context: Amid the EU antitrust probe, Align Technology is also undergoing a board shakeup, with Kevin Conroy set to succeed retiring Chairman C. Raymond Larkin, which may influence the company's strategic direction moving forward.
See More
Align Technology Responds to EU Investigation
- Investigation Response: Align Technology has responded to the European Commission's June 30 announcement regarding an investigation, asserting its commitment to global competition laws and the belief that fair competition fosters innovation and improves outcomes for doctors and patients.
- iTero Platform Strength: The iTero intraoral scanning platform performs millions of scans annually, supporting diverse clinical workflows while ensuring clinical quality and patient safety, showcasing its competitive edge in the digital dentistry market.
- Market Impact: Since 2018, the iTero scanner has facilitated over 24 million scans by healthcare professionals, highlighting its extensive application and influence in the teeth-straightening market, driving diversification in digital dentistry solutions.
- Commitment to Cooperation: Align Technology expresses its intention to fully cooperate with the European Commission's investigation, anticipating that the review will reflect the vibrancy and compliance of the teeth-straightening market, further solidifying its market position.
See More
European Commission Launches Antitrust Investigation into Align Technology
- Antitrust Investigation Launched: The European Commission has initiated an antitrust investigation into Align Technology, alleging that the company tied its Invisalign products to its iTero intra-oral scanners, potentially stifling competition and harming its reputation.
- Concerns Over Market Dominance: The Commission is worried that Align Technology may have unfairly leveraged its market-leading Invisalign clear aligners by effectively forcing dental professionals to purchase the iTero scanner to order Invisalign for their patients, which could lead to market inequities.
- Restrictive Interoperability Strategy: The investigation focuses on Align's so-called 'restrictive interoperability strategy,' which includes refusal to approve competing state-of-the-art scanners and refusal to accept dental professionals' submissions of scans, potentially hindering industry innovation.
- Uncertain Financial Outlook: Although Align Technology forecasts Q2 revenue between $1.04 billion and $1.06 billion and reaffirms a 3%-4% revenue growth for 2026, the antitrust investigation may negatively impact its future performance.
See More
